Effect of 5-HT2C receptor antagonist RS 102221 on mouse behavior

Bulletin of Experimental Biology and Medicine

Volumn 142, Issue 1, 2006, Pages 76-79

  Kuznetsova, E G ^b   Amstislavskaya, T G ^a   Shefer, E A ^a   Popova, N K ^a  

^a INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

^b NOVOSIBIRSK STATE UNIVERSITY   (Russian Federation)

Author keywords

5 HT2C receptors; Anxiety; Behavior; RS 102221; Startle reflex

Indexed keywords

8 [2,4 DIMETHOXY 5 (4 TRIFLUOROMETHYLSULFO AMIDO)PHENYL 5 OXOPHENYL] 1,3,8 TRIAZASPIRO[4,5]DECAN 2,4 DION; 8 [4 (5 AMINO 2,4 DIMETHOXYBENZOYL)BUTYL] 1,3,8 TRIAZASPIRO[4.5]DECANE 2,4 DIONE; SEROTONIN 2C ANTAGONIST; SEROTONIN RECEPTOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG; SEROTONIN 2C RECEPTOR; SPIRO COMPOUND; SULFONAMIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; LIGHT DARK CYCLE; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; OPEN FIELD TEST; STARTLE REFLEX; TRANQUILIZING ACTIVITY; ANIMAL; CBA MOUSE; COMPARATIVE STUDY; DRUG EFFECT; DRUG POTENTIATION; NONPARAMETRIC TEST;

ANIMALS; ANXIETY; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MICE, INBRED CBA; MOTOR ACTIVITY; RECEPTOR, SEROTONIN, 5-HT2C; SPIRO COMPOUNDS; STARTLE REACTION; STATISTICS, NONPARAMETRIC; SULFONAMIDES;

EID: 33750440530     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-006-0296-8     Document Type: Article

References (11)

1. R. Komer, Behavioral Pathopsychology. Mental Disorders and Abnormalities [in Russian], St. Petersburg (2002).
2. A. V. Kulikov, V. A. Kulikov, and D. V. Bazovkina, Zh. Vyssh. Nervn. Deyat., 55, No. 1, 116-122 (2005).
3. N. K. Popova, N. N. Barykina, T. A. Alyokhina, et al., Ros. Fiziol. Zh., 87, No. 8, 80-86 (1999).
4. D. W. Bonhaus, K. K. Weinhardt, M. Taylor, et al., Neuropharmacology, 36, No. 4-5, 621-629 (1997).
5. J. F. Cryan and I. Lucki, J. Pharmacol. Exp. Ther., 295, No. 3, 1120-1126 (2000).
6. F. Jenck, M. Bos, J. Wichmann, et al., Expert. Opin. Investig. Drugs, 10, 1587-1599 (1998).
7. G. Mengod, M. Pompeiano, M. I. Martinez-Mir, and J. M. Palacios, Brain Res., 524, No. 1, 139-143 (1990).
8. B. A. Nic Dhonnchadhala, M. Bourin, and M. Hascoet, Behav. Brain Res., 140, Nos. 1-2, 203-214 (2003).
9. A. Serretti, P. Artioli, and D. De Ronchi, Expert. Opin. Ther. Targets, 8, No. 1, 15-23 (2004).
10. P. D. Shilling and D. Fiefel, Psychopharmacology (Berlin), 164, No. 3, 285-293 (2002).
11. N. R. Swerdlow and M. A. Geyer, Schizophr. Bull., 24, No. 2, 285-301 (1998).